American companies approach USTR against India’s medical price control measures

Vastavam web:  American companies producing medical devices and health information systems have approached the US Trade Representative against India’s move to implement price controls on coronary stents and knee replacement implants that they say denying them equitable market access.

In a petition, the Advanced Medical Technology Association (AdvaMed) president and CEO Scott Whitaker requested the US Trade Representative (USTR) to “suspend or withdraw” India’s benefits under Generalised System of Preferences (GSP).

Scott said that their intention was not for India to lose the benefits of GSP, but rather to advance engagement and meaningful discussions on restoring market access for medtech in India while keeping patients interests at the center of all discussions.Scott alleged that India’s focus on controlling prices of high-quality medical devices, without any attempt to address the larger picture and correct inefficiencies in the health care system, would not achieve its intended benefits.Scott warned that failure to implement a mutually acceptable alternative could deter global organisations from making their latest products available to India s health care providers and patients, make Indian innovators less competitive in global markets, negatively impact future investment in India, and ultimately harm patients.